What is Enlivex Therapeutics Ltd.'s Shariah compliance score?

Enlivex Therapeutics Ltd.'s (ENLV) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Enlivex Therapeutics Ltd. pass AAOIFI screening?

Enlivex Therapeutics Ltd. (ENLV) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (ENLV: 3.9%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 8,200+ stocks at halalscreener.app.

How much purification is needed for Enlivex Therapeutics Ltd. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Enlivex Therapeutics Ltd. (ENLV) using the latest financial data.

Where can I screen Enlivex Therapeutics Ltd. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Enlivex Therapeutics Ltd. (ENLV) and 7,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about ENLV's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

ENLVNot HalalF

Unlock full report, free

ENLV: Is Enlivex Therapeutics Ltd. Halal?

Enlivex Therapeutics Ltd.

NASDAQHealthcareIL

$2.01

Price as of Aug 11, 2026

Market Cap: 33.8M

Screened on a market cap of 16.5M

Compliance Status

Not Halal

Screened on Sep 12, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Enlivex Therapeutics Ltd. (ENLV) halal? Not Halal. Based on AAOIFI screening, Enlivex Therapeutics Ltd. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Enlivex Therapeutics Ltd. (ENLV) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 12, 2026. Source: https://halalscreener.app/en/stock/ENLV

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

3.9% of 30.0% limit

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding ENLV

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Get an email if ENLV's halal status changes

We re-screen Enlivex Therapeutics Ltd. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

Interest-bearing deposits are over the 30% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 12, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

See why ENLV is rated Not Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

Compliance History

Not Halalnow
since Sep 2026
Doubtful
until the change above
Halal
until the change above
Under Review
until the change above
Doubtful
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

RGCA+

Regencell Bioscience Holdings Limited

$5.02

-4.92%

0001.KLA+

Supercomnet Technologies Bhd

$0.48

-0.01%

0002.KLA+

Kotra Industries Bhd

$3.81

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.43

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.37

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track ENLV and 8,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Enlivex Therapeutics Ltd. (ENLV) halal to invest in?

Enlivex Therapeutics Ltd. (ENLV) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Enlivex Therapeutics Ltd. get a F compliance rating?

Enlivex Therapeutics Ltd. (ENLV) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 3.9% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Enlivex Therapeutics Ltd.'s Shariah verdict?

Enlivex Therapeutics Ltd.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Enlivex Therapeutics Ltd. re-screened for Shariah compliance?

Enlivex Therapeutics Ltd. (ENLV) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.